In 2018, Michigan Medicine’s Randolph Regal and Peter Higgins took a bold approach to treat acute severe ulcerative colitis by turning to a newly approved drug, tofacitinib. Despite initial skepticism, their strategy shows promising results, challenging traditional treatments and offering hope for patients who haven’t responded to other therapies. Curious to learn how this unexpected strategy is reshaping the future of ulcerative colitis treatment? Keep reading.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.